Private Placement

enGene hits the road for key investor conferences, showcasing a promising non-viral gene therapy for a tough-to-treat bladder cancer. Will it succeed?

The biotech firm landed $1M at a premium, a sign of investor faith. But with past regulatory hurdles, can this cash pave a new path for its NurOwn® therapy?

The junior explorer secures crucial funding from a renowned investor, fueling its nickel-copper ambitions in Canada's critical mineral heartland.

As Europe's landmark MiCAR regulation takes hold, KuCoin EU expands its Vienna compliance team, signaling a strategic shift toward regulated growth.

Sai Life Sciences' plan to hire 700+ professionals underscores a global shift, positioning India as a critical hub for pharmaceutical R&D and manufacturing.

Telehealth firm MangoRx reports explosive growth with its $99/month TRT program, challenging competitors and raising questions about the future of virtual care.

A new investment aims to bolster NYC's grid with battery storage, but developers face a charged debate between climate goals and community safety fears.

Aventura Private Wealth closes its second Anduril offering, signaling a major shift as private capital floods into high-tech defense disruptors.

MARBLEX's ambitious AI-powered MMO aims to redefine creation, but past criticisms and technical hurdles cast a shadow on its grand vision for Steam.

INmune Bio will present key Phase III results for CORDStrom, a systemic cell therapy for the devastating rare skin disease RDEB. Will it be a breakthrough?

CorroHealth's CPO Becky Blake earns a top leadership award, shining a light on the crucial, yet complex, role of HR in fueling rapid health tech growth.

Klothea Bio's trial for a 'longevity protein' drug in Honduras pushes the boundaries of science, but raises questions about offshore research and equity.

A new fund combines nuclear energy and AI tech, betting that one can solve the other's massive power problem. But is it a brilliant strategy or a risky gamble?

A new service promises to decode and counter viral misinformation in 24 hours, offering brands a rapid-response weapon in the age of digital deception.

A new partnership between USGBC California and Green Badger aims to eliminate the paperwork nightmare of green building, making sustainability truly scalable.

As it heads to key conferences, Orchestra BioMed is pitching its novel pacemaker-based hypertension treatment and a unique drug-eluting balloon.

The cannabis giant's landmark debt deal signals new institutional confidence, but a high interest rate reveals the industry's costly reality.

Reunion Neuroscience hits the investor conference circuit, seeking capital to advance its groundbreaking psychedelic-inspired therapies for depression and anxiety.

With new kits for complex cell models, Atrandi's semi-permeable capsules challenge market leaders by enabling multi-step workflows previously out of reach.

The PXM leader surpassed the coveted 'Rule of 40' financial benchmark in 2025, signaling strong growth and profitability as it preps for an AI-driven future.